Biliary atresia or extra hepatic ductopenia is an acquired disease of the liver. This disease is characterized by the obliteration of the extra hepatic biliary system which results in obstruction of the bile flow from the liver to gall bladder. This can lead to damage to the liver or liver cirrhosis and can become fatal if not treated at an early stage. It occurs because biliary ducts are not normally developed in infants. Currently, there is no known cause of biliary atresia. However, various studies suggest that Reovirus 3 infection, congenital cytomegalovirus infection, and congenital malformation might be responsible for causing biliary atresia in humans. Some of the symptoms associated with biliary atresia are pale or clay-colored stool, jaundice, dark urine, slow or no weight gain, mild hepatomegaly, and enlarged spleen. The treatment regimen widely used to treat biliary atresia can be medications including bile acids, glucocorticoids and antibiotics, and surgical procedure. The most common treatment is a surgical operation called Kasai procedure (connects liver to the intestine for the flow of bile) which is successful if performed before the baby is eight weeks old. However, a liver transplant may or may not be needed depending on the future condition of the baby. The three forms of biliary atresia are: type I or perinatal biliary atresia, type II or biliary atresia splenic malformation, and type III or cystic biliary atresia.
Rise in incidence of biliary atresia is the primary factor contributing to the growth of the biliary atresia treatment market. Moreover, other factors such as high demand for safe and effective pharmacological therapies fuel the growth of the market. Furthermore, increasing patient population and introduction of innovative products are expected to drive the untapped biliary atresia treatment market. However, rise in overall health care expenditure and safety concerns are the major factors likely to hamper the growth of the biliary atresia treatment market in the near future.
The global biliary atresia treatment market can be segmented based on type of treatment. In terms of type of treatment, the market can be sub-segmented into medication and surgery. Medications can be categorized into bile acids such as ursodiol, glucocorticoids such as methylprednisolone and antibiotics such as trimethoprim-sulfamethoxazole. Surgical procedure involved in the treatment of biliary atresia is Kasai hepatoportoenterostomy (HPE).
Geographically, the global biliary atresia treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Asia Pacific is the largest market for biliary atresia treatment products owing to high incidence and prevalence rates of biliary atresia. Various studies conducted on biliary atresia suggests that the overall incidence rate of biliary atresia in countries in Asia is 1 per 8,000 live births. Moreover, it is more common in infants in China as compared to those in Japan. However, the overall incidence rate of biliary atresia in the U.S. is 1 per 10,000 to 15,000 live births, while it is approximately 1 in 12,000 births in Europe.
Key companies and research institutes engaged in the development of biliary atresia treatment are AstraZeneca plc, Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Johnson & Johnson Services Inc., Novartis International AG, Pfizer, Inc., the University of Pennsylvania, and the University of Texas.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.